1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

• ChemBase编号: 333
• 分子式: C22H22FN3O2
• 平均质量: 379.4273832
• 单一同位素质量: 379.16960518
• SMILES: Fc1ccc(C(=O)CCCN2CCC(=CC2)n2c3c([nH]c2=O)cccc3)cc1
• Canonical SMILES: Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c(=O)[nH]c2c1cccc2
• InChI: InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
• InChIKey: RMEDXOLNCUSCGS-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
• IUPAC传统名: halkan; droperidol
• 商标名: DHBP; Dehidrobenzperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Halkan; Inappin; Inapsin; Inapsine; Innovan; Innovar; Innovar-Vet; Inopsin; Inoval; Leptanal; Leptofen; McN-JR 4749; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm
• 别名: Droperidol; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; Droperidol; 1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone

登记号

• CAS号: 548-73-2
• EC号: 208-957-8
• MDL号: MFCD00083290
• PubChem SID: 46505291; 24278357; 160963796
• PubChem CID: 3168
• ATC码: N05AD08
• CHEMBL: 1108
• DrugBank ID: DB00450
• KEGG ID: D00308
• 美国药典/FDA物质标识码: O9U0F09D5X
• 维基百科标题: Droperidol

理论计算性质

JChem

• Acid pKa: 12.716239
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 1.7410331
• LogD (pH = 7.4): 2.9261823
• Log P: 3.014258
• 摩尔折射率: 109.5173 cm^3
• 极化性: 40.190292 Å^3
• 极化表面积: 52.65 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.93
• LOG S: -3.59
• 溶解度: 9.66e-02 g/l

分子性质

理化性质

• 溶解度: 4.21 mg/L
• 疏水性(logP): 2.8

安全信息

• RTECS编号: DE2100000
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22
• 安全公开号: 36
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• 保存温度: 2-8°C

药理学性质

• 作用靶点: Others
• 给药途径: Intravenous, Intramuscular
• 半衰期: 2.3 hours
• 代谢: Hepatic
• 法定药品分级: Rx-only (US)
• 妊娠期药物分类: C (US)
• 相关基因信息: human ... DRD1(1812), DRD2(1813), KCNH1(3756), KCNH2(3757)

产品相关信息

• 纯度: 98%
• 成盐信息: Free Base
• Empirical Formula (Hill Notation): C22H22FN3O2

详细说明

DrugBank - DB00450

• Drug Groups: approved
• Description: A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
• Indication: Droperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
• Pharmacology: Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias.
• Toxicity: The intravenous LD₅₀ of droperidol is 20-43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11-13 mg/kg in rabbits. The intramuscular LD₅₀ of droperidol is 195 mg/kg in mice, 104-110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs. The manifestations of droperidol overdosage are an extension of its pharmacologic actions.
• Affected Organisms: Humans and other mammals
• Biotransformation: Extensively metabolized.
• Absorption: Completely absorbed following intramuscular administration.
• Half Life: Biphasic distribution. The rapid distribution phase is 1.4 ± 0.5 minutes and the slower distribution phase is 14.3 ± 6.5 minutes. Elimination half-life in adults is 134 ± 13 minutes and may be increased in geriatric patients. In children, it is 101.5 ± 26.4 minutes.
• External Links: Wikipedia; RxList; Drugs.com

Sigma Aldrich - D1414

Biochem/physiol Actions
D1, D2 dopamine receptor antagonist; butyrophenone antipsychotic and anti-emetic.